Tesamorelin
A GHRH analog FDA-approved as Egrifta® — studied for reducing visceral (deep abdominal) fat.
Tesamorelin is a growth-hormone-releasing hormone analog. It’s FDA-approved as Egrifta® for HIV-related lipodystrophy and is used off-label by physicians for its effect on visceral adipose tissue and body composition.
Prescription required. Final clinical decisions rest with the prescribing physician.
What is Tesamorelin?
Tesamorelin is a stabilized GHRH analog that selectively stimulates growth-hormone release. Clinically, it’s best known for reducing visceral adipose tissue — the deep abdominal fat associated with metabolic risk — which is the basis of its FDA approval (as Egrifta®) for HIV-related lipodystrophy.
Physicians also use it off-label for body composition in carefully selected patients. It’s available both as the FDA-approved product and as compounded strengths through licensed pharmacies under prescription.
Potential benefits
Visceral fat reduction
Selectively targets deep abdominal (visceral) fat — the basis of its FDA approval.
Body composition
Used off-label by physicians to support body composition in selected patients.
GHRH-driven
Stimulates the body’s own growth-hormone release.
FDA-approved option
Available as Egrifta® as well as compounded strengths.
How it works
How it’s taken
A daily subcutaneous injection. Dose and duration are set by the prescribing physician based on your goals and labs.
Typical protocol
Often evaluated over several months with periodic reassessment of response and tolerability.
How ordering works
Complete the intake
Share your goals, health history, and current medications — about 5 minutes.
Physician evaluation
An independent, board-certified physician reviews your intake and, if appropriate, prescribes Tesamorelin with a dosing protocol.
Compounded & shipped
The prescription is filled by a licensed compounding pharmacy and shipped to your door with instructions.
What to know before Tesamorelin
Tesamorelin is a bioactive compound. The physician you’re connected with will review the relevant risks and contraindications for your situation before prescribing.
- •Injection-site reactions are common; joint pain or swelling (edema) can occur.
- •Can affect glucose/blood sugar — periodic monitoring is recommended.
- •Active cancer or recent malignancy is a contraindication for GH-stimulating therapy.
- •Pregnancy and breastfeeding are contraindications for most peptides.
- •Disclose your full medical history; the physician will confirm whether Tesamorelin is appropriate for you.
Tesamorelin FAQ
What is Tesamorelin used for?
It’s a GHRH analog FDA-approved (as Egrifta®) for HIV-related lipodystrophy and used off-label by physicians to reduce visceral fat and support body composition.
Is Tesamorelin FDA-approved?
Yes — the Egrifta® formulation is FDA-approved for a specific indication. Compounded strengths and off-label use are prescribed under physician supervision.
How is it taken?
A daily subcutaneous injection; the physician you’re connected with sets your dose and duration.
How long until results?
Visceral-fat changes are typically assessed over months. Your physician will set expectations for your situation.
How much does it cost?
Tesamorelin starts from $299/month. Final pricing is confirmed after your physician evaluation. The initial evaluation is free.
Ready to start Tesamorelin?
Complete a short medical intake — a supervising physician reviews it and, if appropriate, writes your prescription, and a licensed pharmacy ships to your door.
Pricing & regulatory note: The $299/mo price is an indicative starting point confirmed by the compounding pharmacy after physician evaluation. Tesamorelin is not an FDA-approved finished drug product; it is prepared by licensed compounding pharmacies and prescribed off-label. FDA guidance on peptide compounding continues to evolve and availability can change. A prescription is required.